These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 16273408)

  • 1. Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
    Yee KW; Jabbour E; Kantarjian HM; Giles FJ
    Ann Hematol; 2005 Dec; 84 Suppl 1():18-24. PubMed ID: 16273408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
    Hackanson B; Robbel C; Wijermans P; Lübbert M
    Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
    Silverman LR; Mufti GJ
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decitabine.
    Hackanson B; Daskalakis M
    Recent Results Cancer Res; 2014; 201():269-97. PubMed ID: 24756800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders.
    Kuykendall JR
    Ann Pharmacother; 2005 Oct; 39(10):1700-9. PubMed ID: 16144884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development of decitabine as a prototype for an epigenetic drug program.
    Rosenfeld CS
    Semin Oncol; 2005 Oct; 32(5):465-72. PubMed ID: 16210087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
    Leone G; Teofili L; Voso MT; Lübbert M
    Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decitabine in myelodysplastic syndromes.
    Saba HI; Wijermans PW
    Semin Hematol; 2005 Jul; 42(3 Suppl 2):S23-31. PubMed ID: 16015501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
    Merkel DG; Nagler A
    Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
    Joeckel TE; Lübbert M
    Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of hypomethylating agents in myelodysplastic syndromes.
    Atallah E; Garcia-Manero G
    Clin Adv Hematol Oncol; 2007 Jul; 5(7):544-52. PubMed ID: 17679928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
    Issa JP; Garcia-Manero G; Huang X; Cortes J; Ravandi F; Jabbour E; Borthakur G; Brandt M; Pierce S; Kantarjian HM
    Cancer; 2015 Feb; 121(4):556-61. PubMed ID: 25336333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment.
    Daskalakis M; Nguyen TT; Nguyen C; Guldberg P; Köhler G; Wijermans P; Jones PA; Lübbert M
    Blood; 2002 Oct; 100(8):2957-64. PubMed ID: 12351408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of epigenetic treatment in myelodysplastic syndromes.
    Kuendgen A; Lübbert M
    Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
    Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP
    Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decitabine.
    Daskalakis M; Blagitko-Dorfs N; Hackanson B
    Recent Results Cancer Res; 2010; 184():131-57. PubMed ID: 20072836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
    Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
    Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients.
    Wijermans PW; Lübbert M; Verhoef G; Klimek V; Bosly A
    Ann Hematol; 2005 Dec; 84 Suppl 1():9-17. PubMed ID: 16211386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of decitabine in the treatment of myelodysplastic syndromes.
    Atallah E; Kantarjian H; Garcia-Manero G
    Expert Opin Pharmacother; 2007 Jan; 8(1):65-73. PubMed ID: 17163808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine.
    Pitako JA; Haas PS; Van den Bosch J; Müller-Berndorff H; Kündgen A; Germing U; Wijermans PW; Lübbert M
    Ann Hematol; 2005 Dec; 84 Suppl 1():25-31. PubMed ID: 16292666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.